Hyaluronan self-agglomerating nanoparticles for non-small cell lung cancer targeting

Abstract Background Owing to the limited amount of research, there are no nanoparticle-based anticancer agents that use hydrophilic drugs. Therefore, we developed irinotecan-loaded self-agglomerating hyaluronan nanoparticles (ISHNs). While irinotecan has high hydrophilicity, resulting nanoparticle should possess drug-loading capacity and allow selective targeting cluster differentiation 44 (CD44) protein, which is overexpressed on surface tumor cells. Results The ISHNs were successfully made with (HA) as a moiety, FeCl 3 binder, D-glutamic acid (GA) stabilizer. self-agglomerated via chelating bonding lyophilized using freeze dryer. particle diameter zeta potential 93.8 ± 4.48 nm − 36.3 0.28 mV, respectively; relatively narrow size distribution was observed. drug fixation yield concentration 58.3% 1.75 mg/mL, respectively. Affinity studies revealed tenfold stronger H23 (CD44 + ) non-small-cell lung cancer (NSCLC) cells, than A549 Conclusion We ISHNs, comprised hydrochloride water-soluble agent, HA binder for self-agglomeration, GA stabilizer; binding material CD44 in NSCLC their ease manufacture, excellent stability, non-cell toxicity CD44-targeting ability, nanocarriers passive active targeting.